中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2011年
9期
956-958
,共3页
孙志芬%邵鹏%邢喜芝%李朋霞%刘玉斌%刘金鹏%王彦敏
孫誌芬%邵鵬%邢喜芝%李朋霞%劉玉斌%劉金鵬%王彥敏
손지분%소붕%형희지%리붕하%류옥빈%류금붕%왕언민
糖尿病肾病%前列地尔%厄贝沙坦%24h尿微量白蛋白
糖尿病腎病%前列地爾%阨貝沙坦%24h尿微量白蛋白
당뇨병신병%전렬지이%액패사탄%24h뇨미량백단백
Diabetic nephropathy%Alprostadil%Irbesartan%24 hour urine albumin
目的 观察前列地尔联合厄贝沙坦治疗早期糖尿病肾病(DN)的临床疗效。方法 收集早期DN患者120例,随机分成3组:厄贝沙坦组40例(厄贝沙坦150 mg,1次/d),前列地尔组40例(生理盐水+前列地尔10 μg静脉滴注),前列地尔联合厄贝沙坦组40例(剂量用法同前)。全部病例进行临床观察4周。分别比较3组血肌酐(Cr)、尿素氮(BUN),24h尿微量白蛋白(24 hUAE)治疗前后的变化。结果 3组患者治疗前后24 hUAE比较差异有统计学意义(t=2.07、t=2.01、t=3.15,P均＜0.05),联合治疗组降低24 hUAE[(252.69±33.56) mg/24 h]的作用优于厄贝沙坦组[(268.75±34.42)mg/24 h](t=2.11,P＜0.05),也优于前列地尔组[(267.95±34.75) mg/24 h](t=1.998,P＜0.05);厄贝沙坦和前列地尔组间差异无统计学意义(P＞0.05)。治疗过程中,前列地尔静脉滴注时个别患者出现滴注部位肿胀、不适,调整滴速后患者上述症状好转,未见其他不良反应。结论 前列地尔与厄贝沙坦联合应用是治疗早期DN的有效方法。
目的 觀察前列地爾聯閤阨貝沙坦治療早期糖尿病腎病(DN)的臨床療效。方法 收集早期DN患者120例,隨機分成3組:阨貝沙坦組40例(阨貝沙坦150 mg,1次/d),前列地爾組40例(生理鹽水+前列地爾10 μg靜脈滴註),前列地爾聯閤阨貝沙坦組40例(劑量用法同前)。全部病例進行臨床觀察4週。分彆比較3組血肌酐(Cr)、尿素氮(BUN),24h尿微量白蛋白(24 hUAE)治療前後的變化。結果 3組患者治療前後24 hUAE比較差異有統計學意義(t=2.07、t=2.01、t=3.15,P均＜0.05),聯閤治療組降低24 hUAE[(252.69±33.56) mg/24 h]的作用優于阨貝沙坦組[(268.75±34.42)mg/24 h](t=2.11,P＜0.05),也優于前列地爾組[(267.95±34.75) mg/24 h](t=1.998,P＜0.05);阨貝沙坦和前列地爾組間差異無統計學意義(P＞0.05)。治療過程中,前列地爾靜脈滴註時箇彆患者齣現滴註部位腫脹、不適,調整滴速後患者上述癥狀好轉,未見其他不良反應。結論 前列地爾與阨貝沙坦聯閤應用是治療早期DN的有效方法。
목적 관찰전렬지이연합액패사탄치료조기당뇨병신병(DN)적림상료효。방법 수집조기DN환자120례,수궤분성3조:액패사탄조40례(액패사탄150 mg,1차/d),전렬지이조40례(생리염수+전렬지이10 μg정맥적주),전렬지이연합액패사탄조40례(제량용법동전)。전부병례진행림상관찰4주。분별비교3조혈기항(Cr)、뇨소담(BUN),24h뇨미량백단백(24 hUAE)치료전후적변화。결과 3조환자치료전후24 hUAE비교차이유통계학의의(t=2.07、t=2.01、t=3.15,P균＜0.05),연합치료조강저24 hUAE[(252.69±33.56) mg/24 h]적작용우우액패사탄조[(268.75±34.42)mg/24 h](t=2.11,P＜0.05),야우우전렬지이조[(267.95±34.75) mg/24 h](t=1.998,P＜0.05);액패사탄화전렬지이조간차이무통계학의의(P＞0.05)。치료과정중,전렬지이정맥적주시개별환자출현적주부위종창、불괄,조정적속후환자상술증상호전,미견기타불량반응。결론 전렬지이여액패사탄연합응용시치료조기DN적유효방법。
Objective To observe the clinical efficacy of combined irbesartan and alprostadil treatment of early diabetic nephropathy (DN).Methods A total of 120 patients with early type 2 diabetes of hospitalization were randomly divided into 3 groups: irbesartan group of 40 patients (150 mg, once per day)(group irbesartan),40 patients treated with alprostadil (physiological saline and alprostadi 10 μg))(group alprostadi) ,40 patients treated with alprostadil combined irbesartan (dose same as the other two groups)(combined group).All cases were observed for 4 weeks.Comparison of serum creatinine (Cr), blood urea nitrogen(BUN) ,24 hour urinary albumin(24hUAE) changes after treatment.Results After treatment 4 weeks 24hUAE of the three groups were significantly decreased (t = 2.07, t = 2.01 and t = 3.15, Ps ＜ 0.05) .The decrease of 24hUAE in the combined treatment group ([252.69 ± 33.56]mg/24h) was better than that in the irbesartan group([268.75 ± 34.42)](t = 2.11, P ＜ 0.05) and in the alprostadil group ([267.95 ± 30.75])mg/24h (t = 1.998, P ＜ 0.05) .No significant difference were observed between the Irbesartan and alprostadil group.During treatment, several patients affected by swell, uncomfortable in the alprostadil group, but improved after treatment.No other adverse effect was observed.Conclusion Alprostadil combined with irbesartan treatment of early diabetic nephropathy is an effective way.
